Italia markets closed

Regeneron Pharmaceuticals, Inc. (0R2M.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a watchlist
966,21+1,22 (+0,13%)
Alla chiusura: 06:53PM GMT

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road
Tarrytown, NY 10591-6707
United States
914 847 7000
https://www.regeneron.com

Settore/i
Settore
Impiegati a tempo pieno13.450

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Dr. Leonard S. Schleifer M.D., Ph.D.Co-Founder, President, CEO & Co-Chairman7MN/D1953
Dr. George D. Yancopoulos M.D., Ph.D.Co-Founder, President, Chief Scientific Officer & Co-Chairman6,59MN/D1960
Dr. Andrew J. Murphy Ph.D.Executive Vice President of Research1,62M19,39M1959
Mr. Daniel P. Van PlewExecutive VP and GM of Industrial Operations & Product Supply1,95M45,28M1973
Ms. Marion E. McCourtExecutive Vice President of Commercial1,5M4,25M1960
Mr. Christopher R. Fenimore CPASenior VP of Finance & CFON/DN/D1971
Ms. Patrice GiloolySenior Vice President of Quality Assurance & OperationsN/DN/DN/D
Mr. Bob McCowanSenior VP of IT & Chief Information OfficerN/DN/DN/D
Mr. Ryan CroweSenior Vice President of Investor Relations & Strategic AnalysisN/DN/DN/D
Mr. Joseph J. LaRosaExecutive VP, General Counsel & Secretary1,75M23,23M1959
Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Governance aziendale

L'ISS Governance QualityScore di Regeneron Pharmaceuticals, Inc. al 1 marzo 2024 è 10. I criteri di valutazione fondamentali sono revisione: 9; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.